



Published in final edited form as:

*Virology*. 2007 April 10; 360(2): 322–328.

## Herpes simplex type 2-mediated disease is reduced in mice lacking RNase L

Rebecca J. Duerst<sup>1</sup> and Lynda A. Morrison<sup>a,\*</sup>

*a* Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104

### Abstract

RNase L helps mediate the antiviral state induced by type I interferons (IFN $\alpha\beta$ ). Although herpes simplex virus (HSV) encodes inhibitors of the IFN $\alpha\beta$ -induced antiviral response, the IFN $\alpha\beta$  system serves the body as a first line of defense against HSV. We investigated whether RNase L limits HSV-2 replication and virulence. RNaseL<sup>-/-</sup> and wild-type C57BL/6 mice were infected intravaginally with HSV-2 strain 333. Although initial replication in the genital epithelium was similar, mice lacking RNase L developed *less* severe genital and neurologic disease than wild-type mice, survived longer, and contained lower viral titers in the nervous system. CD4<sup>+</sup> T cell infiltration into the genital tract and spinal cord of RNase L<sup>-/-</sup> mice was reduced, suggesting that a restricted inflammatory response may account for reduction in disease. Thus, RNase L does not play a significant role in control of HSV-2 infection *in vivo*; instead RNase L may regulate aspects of the inflammatory response that contribute to disease.

### Introduction

The innate IFN $\alpha\beta$  response exerts potent antiviral activity in part by causing RNA degradation and translational arrest in virus-infected cells to limit virus replication and spread. IFN $\alpha\beta$  are produced by most cells in response to virus infection, and they initiate a signal transduction cascade by binding the IFN $\alpha\beta$  receptor (IFN $\alpha\beta$ R) on uninfected cells to stimulate transcription of genes that prime for an antiviral state that is activated upon virus infection. Among the many antiviral pathways induced by IFN $\alpha\beta$ , one prominent antiviral function is mediated by protein kinase R (PKR), which phosphorylates eIF2 $\alpha$  to arrest translation. The oligoadenylate synthetase (OAS)/RNase L pathway is another of the most extensively characterized. IFN $\alpha\beta$  signaling stimulates synthesis of OAS and RNase L (Floyd-Smith, 1988), and once the cell is infected, viral double-stranded RNA (dsRNA) activates OAS to produce 2'5'-linked oligoadenylates (2'5'A). The 2'5'A then activate RNase L to degrade RNA, resulting in translation inhibition and blockade of viral replication.

*In vivo*, herpes simplex virus (HSV) infections typically initiate in a moist epithelial surface. Virus quickly spreads from the epithelium into sensory nerves to establish latent infection. Innate immune responses, particularly the IFN $\alpha\beta$  response, are essential during the first few days of infection to limit HSV replication in the epithelium and spread into the nervous system.

\*Corresponding Author. Mailing address: Dept. of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, 1402 S. Grand Blvd., St. Louis, MO 63104. Phone: (314) 977-8874. Fax: (314) 977-8717. E-mail: morrisla@slu.edu

<sup>1</sup>Current address: Dept. of Microbiology, University of Minnesota, 402 Delaware St. S.E., Minneapolis, MN 55455. E-mail: duers007@umn.edu

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

In mouse models of HSV-1 ocular infection, neutralization of IFN $\alpha\beta$  results in a 1000-fold increase in titer of HSV-1 shed from the cornea (Hendricks et al., 1991; Lausch et al., 1991). Expression of IFN $\alpha\beta$  in the cornea via plasmid DNA transfection or adenovirus-mediated transduction limits replication and enhances survival after corneal infection with HSV-1 (Noisakran et al., 1999; Al-khatib et al., 2004; Austin et al., 2005; Al-khatib et al., 2005). IFN $\alpha\beta$  also have a protective role against HSV-1 infection in vitro, reducing viral immediately early ( $\alpha$ ) gene expression (Klotzbucher et al., 1990; Mittnacht et al., 1988; Oberman and Panet, 1988; Oberman and Panet, 1989) and viral yield in fibroblasts (Harle et al., 2002b; Noisakran et al., 2000; Harle et al., 2002a; Khabar et al., 2000) and cells of neural origin (Al-Khatib et al., 2003; Carr et al., 2003). The IFN $\alpha\beta$  response is an important component of host resistance during HSV-2 replication in the genital epithelium, limiting virus spread to the lumbosacral spinal cord and preventing neurologic disease (Murphy et al., 2003). Expression of IFN $\alpha$ 1 in the vaginal epithelium prior to infection further reduces HSV-2 replication and virulence (Harle et al., 2001).

Although the IFN $\alpha\beta$  response intercedes in the early stages of HSV-1 and HSV-2 infections, these neurotropic viruses have developed resistance mechanisms to partially overcome its effects. For example, HSV inhibits IFN $\alpha\beta$ -induced antiviral activities mediated by PKR through the actions of ICP34.5 and Us11 (Cassady et al., 1998b; He et al., 1997). HSV-1  $\gamma$ 34.5 null mutants are severely attenuated in wild-type mice, but restored in PKR<sup>-/-</sup> mice (Leib et al., 2000), and the absence of ICP34.5 can be compensated by expression of Us11 as an immediate-early gene (Cassady, Gross et al., 1998a). Furthermore, replication and virulence of wild-type virus is not enhanced in the absence of PKR (Harle et al., 2001; Leib et al., 2000), demonstrating that HSV effectively blocks PKR-mediated antiviral activity using these proteins. However, wild-type HSV replicates more readily in mice that lack the IFN $\alpha\beta$ R (Murphy et al., 2003; Leib et al., 1999), a finding which indicates the existence of additional IFN $\alpha\beta$ -induced antiviral pathways capable of suppressing wild-type HSV growth in vivo.

Evidence has accumulated for the activity of the OAS/RNase L pathway in protecting against HSV infection. In vitro, HSV-1 replicates to higher titers in RNase L<sup>-/-</sup> murine embryonic fibroblasts (MEFs) and trigeminal ganglion neurons than in wild-type cells (Harle et al., 2002b; Carr et al., 2003), suggesting a role for RNase L in countering HSV infections. In vivo, however, an antiviral function for RNase L remains controversial. Studies supporting an antagonistic role have shown an increase in replication of HSV-1 in the corneal epithelium of RNase L<sup>-/-</sup> mice (Austin et al., 2005), and more severe ocular disease and higher mortality (Zheng et al., 2002) compared to wild-type mice. Yet contrasting results indicate that HSV-1 replication is not enhanced in the corneal epithelium (Leib et al., 2000; Al-khatib et al., 2004) and trigeminal ganglia (Al-khatib et al., 2004; Austin et al., 2005) of RNase L<sup>-/-</sup> mice, and neither is overall virulence (Al-Khatib et al., 2005). This lack of effect could be explained by the purported induction by HSV-1 of 2'5'A analogs that have diminished capacity to activate RNase L (Cayley et al., 1984).

The role of the OAS/RNase L pathway in mediating IFN $\alpha\beta$ -induced protection against HSV-2 replication and spread is not known. Although some data support a role for RNase L as an HSV-1 antagonist, differences between HSV-1 and HSV-2 have been found regarding their mechanisms of resistance to mediators of IFN $\alpha\beta$ -induced antiviral effects (Murphy et al., 2003). Thus, the role of RNase L during HSV-2 genital infection may differ from its role in protecting the cornea against infection with HSV-1. We therefore investigated whether the OAS/RNase L pathway plays an important role in host resistance to HSV-2 by examining virus replication and disease induction during primary genital infection of wild-type and RNase L<sup>-/-</sup> mice.

## Results

RNase L is a mediator of the IFN $\alpha\beta$  response, and IFN $\alpha\beta$  plays an important role in the innate antiviral response against HSV-2 *in vivo* (Murphy et al., 2003). To determine whether RNase L contributes to host defense against primary HSV-2 infection, wild-type C57BL/6 and RNase L<sup>-/-</sup> mice were infected by the intravaginal (i.vag.) route with 2×10<sup>6</sup> pfu/mouse of HSV-2 strain 333. Titers of virus shed from the genital epithelium and genital disease were assessed. 2'5'-OAS is upregulated in the genital epithelium 24 hr after HSV-2 infection (Palliser et al., 2006). We therefore expected that if activated RNase L mediates a vital antiviral response to HSV-2 in genital epithelial cells, RNase L<sup>-/-</sup> mice would show prolonged virus replication and more severe disease than wild-type mice. However, replication of HSV-2 in the genital epithelium of RNase L<sup>-/-</sup> and wild-type mice was similar at all time points (Fig. 1). Thus it appears IFN $\alpha\beta$ -stimulated pathways other than those mediated by OAS/RNase L are important for controlling HSV-2 replication in cells in the genital epithelium. Alternatively, HSV-2 may have evolved mechanisms that effectively counteract RNase L-mediated antiviral responses in the genital mucosa, thus neutralizing RNase L-mediated effects.

Surprisingly, despite virtually identical levels of virus replication in the epithelium, signs of genital disease developed more slowly in RNase L<sup>-/-</sup> mice than in wild-type mice (Fig. 2A). Inflammation of the external genitalia was less pronounced in RNase L<sup>-/-</sup> mice than wild-type mice on days 4 to 6 post-infection (p<0.001). Genital lesions were present in 70% of wild-type mice on day 5 and in 100% on day 6, but RNase L<sup>-/-</sup> mice did not develop lesions until day 6, when only 49% of the mice were affected (p<0.0001 for days 5 and 6). Signs of neurologic disease were also greater in wild-type mice, with 61% developing hind-limb paralysis by day 6. In contrast, only 12% of RNase L<sup>-/-</sup> mice became paralyzed (p<0.0001). Delayed development of HSV-2-mediated disease in RNase L<sup>-/-</sup> mice was reflected in their slower weight loss as infection progressed (Fig. 2B; p<0.0001 on days 5 and 6 post-infection). Survival times also differed between wild-type and RNase L<sup>-/-</sup> mice (Fig. 3). On day 6, all RNase L<sup>-/-</sup> mice were alive, compared with 53% of wild-type mice (p=0.0003). On day 7, 59% of RNase L<sup>-/-</sup> mice were surviving, but only 21% of wild-type mice were still alive (p=0.0252). Overall, the mean day of death for RNase L<sup>-/-</sup> mice was 8.0±1.3, but wild-type mice succumbed by a mean of 6.8±1.0 days post-infection (p=0.0021). These data indicate similar kinetics of virus replication in the genital epithelium but slower development of genital inflammation and neurologic signs in mice lacking RNase L. The delayed onset of inflammation and neurologic disease in RNase L<sup>-/-</sup> mice corresponded with their slower demise.

Delayed development of neurologic signs and death in RNase L<sup>-/-</sup> mice could be due to decreased virus replication in the central nervous system (CNS), or to decreased inflammation contributing to paralysis. To address these possibilities, we first determined viral titer in the CNS of mice 6 days post-infection, when neurologic signs were apparent. Virus titers in the spinal cords of RNase L<sup>-/-</sup> mice were 3-fold lower than in wild-type B6 mice (p=0.0152) and 6-fold lower in the brainstems (p=0.0116; Fig. 4A). Thus, HSV-2 entered into or replicated in the nervous systems of RNase L<sup>-/-</sup> mice less efficiently than wild-type mice, despite replicating equally well in the genital mucosae of both mouse strains. Direct intracranial injection of virus revealed no difference in capacity of HSV-2 to replicate in brain tissue of RNase L<sup>-/-</sup> or wild-type mice (Fig. 4B), suggesting that a difference in neuroinvasion rather than neurovirulence accounted for the reduced titers of HSV-2 in the spinal cords and brainstems of RNase L<sup>-/-</sup> mice.

We examined the additional possibility that a difference in activation or recruitment of inflammatory infiltrates into infected tissues resulted in less inflammation in RNase L<sup>-/-</sup> mice and therefore reduced signs of disease. Six days post-infection, vaginas and lumbosacral spinal

cords were dissected, subjected to collagenase digestion, and mononuclear cells were isolated over Percoll gradients. Phenotypic staining followed by flow cytometry revealed that i) infiltration of mononuclear cells in the vaginas and spinal cords increased markedly in all infected mice relative to uninfected controls. ii) The proportion of activated (CD69<sup>+</sup>) cells among CD4<sup>+</sup> and CD8<sup>+</sup> T cells infiltrating the vaginas and spinal cords of wild-type and RNase L<sup>-/-</sup> mice was similar. iii) The influx of CD8<sup>+</sup> T cells into tissues was relatively small, and the percentage (Fig. 5A) and number (Fig. 5B) of CD45<sup>+</sup>CD8<sup>+</sup> lymphocytes was higher in the vaginas of infected RNase L<sup>-/-</sup> mice than wild-type mice but not significantly different in the spinal cords. In contrast, iv) the percentage of CD45<sup>+</sup>CD4<sup>+</sup> lymphocytes was lower in both the vaginas and spinal cords of infected RNase L<sup>-/-</sup> mice (Fig. 5C), and quantification of infiltrating CD4<sup>+</sup> lymphocytes revealed similar trends (Fig. 5D). The latter observation suggests that fewer CD4<sup>+</sup> T cells had entered the infected tissues in RNase L<sup>-/-</sup> mice than wild-type mice, and this delayed the development of inflammation.

## Discussion

Contrary to our expectation that HSV-2 would replicate more readily and cause more disease in RNase L-deficient mice after primary genital infection, we found that disease caused by HSV-2 infection is *milder* in RNase L<sup>-/-</sup> mice than wild-type mice. Viral replication, although similar in the vaginal epithelium, is modestly *lower* in the nervous system of RNase L<sup>-/-</sup> mice. Thus, RNase L is not necessary for resistance to primary HSV-2 infection *in vivo*, at least as assessed by genetic deletion. Although the differences in viral titers in the spinal cords and brainstems of RNase L<sup>-/-</sup> mice compared with wild-type mice are modest, small reductions in virus replication in the CNS may have profound effects on survival time, in that a threshold may exist for causing paralytic or lethal neurologic disease. Viral titers in the nervous systems of wild-type mice may have reached this threshold more often and more quickly than in RNase L<sup>-/-</sup> mice. Because a small number of wild-type mice died before CNS tissues were collected for determination of viral titer day 6 post-infection, the difference in viral titers we observed (Fig. 4A) may underestimate the true magnitude of the difference in replication of HSV-2 in the CNS of wild-type and RNase L<sup>-/-</sup> mice on day 6. We did not evaluate earlier time points, and thus it is possible that titers in the spinal cords of wild-type and RNase L<sup>-/-</sup> mice may be equivalent initially and then gradually diverge.

Certain antiviral effector molecules such as RNase L may play a more significant role in resistance to HSV infection if upregulated by IFN $\alpha\beta$  exposure prior to infection than they do in the natural course of response to primary infection. Indeed, IFN $\beta$  pretreatment suppresses HSV-1 replication in MEFs or in cells derived from the trigeminal ganglia by a mechanism requiring RNase L (Carr et al., 2003). Primary HSV-2 infection of vaginal epithelial cells would be expected to stimulate some IFN $\alpha\beta$  to protect neighboring cells in advance of subsequent rounds of virus replication. Thus, it would be predicted that HSV should replicate more readily in RNase L-deficient mice. Instead, replication is similar in the vaginal epithelium, indicating that RNase L activity does not limit HSV-2 replication during primary genital infection of mice with HSV-2. The role of RNase L may be usurped by other antiviral mechanisms in the vaginal epithelial cells, creating no net change in virus replication. In contrast to the vaginal epithelium, virus titer in the spinal cord and brainstem of RNase L<sup>-/-</sup> mice is modestly restricted, but how RNase L affects virus titer is unclear. A subtle difference in genetic background between wild-type and mutant mice cannot be ruled out but is unlikely to be the sole cause of the disparity in titers. Reduced spinal cord and brainstem titers after peripheral inoculation of virus may result from differential neuroinvasion rather than neurovirulence, as suggested by the observation that virus grew to equivalent titers after direct introduction into the nervous systems of RNase L<sup>-/-</sup> and wild-type mice. The lesser influx of inflammatory cells into the spinal cords of RNase L<sup>-/-</sup> mice may relate to neuroinvasion by delaying an increase in vascular

permeability or by restricting virus entry in association with leukocytes trafficking into the tissue.

A surprising finding was the delayed development of severe genital inflammation, genital lesions and paralysis in mice lacking RNase L, suggesting that RNase L plays a potentiating role in some aspects of HSV infection, whether directly or indirectly. At least three possibilities may be entertained to explain the mechanism underlying this observation. First, disruption of a synergistic relationship between the ribonuclease activities of the virion host shutoff (vhs) protein and host RNase L could explain the increased survival in RNase L<sup>-/-</sup> mice. However, Northern analysis of GAPDH mRNA revealed that mRNA degradation was equivalent in wild-type and RNase L<sup>-/-</sup> MEFs infected with HSV-2 (data not shown), in accord with previous observations with HSV-1 (Smith et al., 2003). Second, HSV-mediated disease may appear less severe in mice lacking RNase L because less apoptotic cell death occurs in infected tissues. Cells derived from mice lacking RNase L undergo apoptosis more slowly or show a deficiency in apoptosis induction (Castelli et al., 1998; Zhou et al., 1998). Apoptosis is not generally associated with erythema and edema, and thus an impact of RNase L on apoptotic cell death probably does not explain decreased signs of genital disease in HSV-2-infected RNase L<sup>-/-</sup> mice. However, this hypothesis could pertain to a possible decrease or delay in neuronal cell death, staving off paralysis and allowing longer survival time.

Finally, there is evidence that RNase L plays a role in modulating T cell responses in that RNase L<sup>-/-</sup> mice reject tissue grafts more slowly than wild-type mice (Silverman et al., 2002). T cells play important roles in host defense against viruses but their activities also can contribute to immunopathology. For example, IFN $\gamma$ -producing CD4<sup>+</sup> T cells have been previously found in the genital tract after primary HSV-2 infection (Milligan and Bernstein, 1995) and may be important for virus clearance (Milligan et al., 2004). However, their activities may also contribute to genital inflammation associated with HSV-2 infection (Harandi et al., 2001; Murphy et al., 2003). Our finding that activated CD4<sup>+</sup> T cells enter the vaginal tracts of RNase L<sup>-/-</sup> mice less frequently than wild-type mice is consistent with this interpretation. Reduced CD4<sup>+</sup> T cell migration into vaginal tissue of RNase L<sup>-/-</sup> mice may delay development of erythema and edema characteristic of the inflammatory response to HSV-2. Similarly, subdued inflammatory influx into the spinal cords of HSV-2-infected RNase L<sup>-/-</sup> mice may delay the onset of paralysis. CD4<sup>+</sup> T cell influx into the CNS consonant with virus infection (Marten et al., 2001; Glass et al., 2005), and subsequent contribution to pathology (Gerety et al., 1994; Lane et al., 2000; Rowell and Griffin, 1999), has been observed in a number of virus-induced CNS diseases. Thus, delaying the pathologic consequences of an effector T cell response within the CNS could enhance the life-prolonging effect of lower viral CNS titers in RNase L<sup>-/-</sup> mice. A small reciprocal increase in the percentage of CD8<sup>+</sup> T cells infiltrating the genital tract of RNase L<sup>-/-</sup> mice was also seen. HSV-specific CD8<sup>+</sup> as well as CD4<sup>+</sup> T cells have been associated with immunopathology in the eye (Niemieltowski and Rouse, 1992; Keadle et al., 2002; Osorio et al., 2004). It is possible that CD8<sup>+</sup> T cells also contribute to genital inflammation, but this contribution is inapparent because CD8<sup>+</sup> T cells comprise a minor proportion of the tissue infiltrates. Further experiments investigating inflammatory cytokine production by T cells and/or apoptosis induction in the genital epithelium and nervous system are needed to determine the mechanism by which the lack of RNase L attenuates HSV-2-mediated disease.

## Materials and Methods

### Cells and viruses

Vero cells were maintained in Dulbecco's modified Eagle's medium supplemented with 3% newborn and 3% fetal calf serum. SB5, a plaque-purified clone of HSV-2 strain 333, was obtained from the American Type Culture Collection (VR-2546). A cell lysate stock was

prepared as previously described (Morrison and Knipe, 1996). Titer of the virus stock was determined by titration on Vero cell monolayers.

## Mice

RNase L<sup>-/-</sup> mice on the C57BL/6 background (Zhou et al., 1997) were generously provided by Bob Silverman. Wild-type C57BL/6 mice were purchased from the National Cancer Institute (Fredericksburg, MD), the same source as previously used by the Silverman laboratory (Silverman et al, 2002; Leitner et al., 2003). RNase L<sup>-/-</sup> mice were bred and maintained in the Department of Comparative Medicine, Saint Louis University School of Medicine in accordance with institutional and Public Health Service guidelines. Mice were used at 6 weeks of age. Several experiments were performed and the data from individual experiments were pooled.

## Genital swab and neural tissue titers

Mice were infected by the i.vag. route with  $2 \times 10^6$  pfu/mouse as previously described (Morrison et al., 1998). Two vaginal swabs per mouse were taken on days 0–4 post-infection using calcium alginate swabs (Puritan Medical Products, Guilford ME) which were placed together in vials containing phosphate-buffered saline and stored at  $-80^\circ\text{C}$ . At 6 to 7 days post-infection, mice were sacrificed and the spinal cord, brainstem, and brain were dissected. Alternatively, groups of mice were inoculated intracranially with  $5 \times 10^3$  pfu of HSV-2 in 10  $\mu\text{l}$  vol using a 29-gauge insulin syringe (Terumo Medical Corp., Somerset NJ). Brain tissue was dissected 1, 2 or 3 days post-infection. Tissues were placed in microcentrifuge tubes containing phosphate-buffered saline and 1-mm glass beads, and stored at  $-80^\circ\text{C}$ . Thawed tissues were disrupted using a Mini BeadBeater 8 (Biospec Products, Bartlesville, OK). Viral titers were determined by standard plaque assay (Knipe and Spang, 1982).

## Disease scores

Severity of genital and neurologic disease was assessed on days 2 through 7 post-infection using the following scale: 0, no signs; 1, mild erythema and edema of the external genitalia; 2, moderate erythema and edema; 3, severe erythema and edema.

## Flow cytometry

Genital tracts from the vaginal orifice to the exocervix and lumbosacral spinal cords were dissected from wild-type and RNase L<sup>-/-</sup> mice 6 days post-infection. Minced tissues were digested in 1 ml of 1 mg/ml dispase/collagenase (Roche Applied Sciences, Indianapolis IN) for 40 min at  $37^\circ\text{C}$ . Cells released from genital tracts were incubated for 4 hr at  $37^\circ\text{C}$  in 12-well plates. Non-adherent cells were collected for staining. Supernatants of spinal cord digests were layered over 30%–70% discontinuous Percoll gradients (Redi-Grad, Amersham Biosciences, Piscataway NJ) and sedimented by centrifugation at 2000 rpm for 20 min. Cells at the interface were collected and washed before staining. Cells from individual mice were incubated with FcBlock (BD PharMingen, San Diego CA) and then stained with a cocktail of anti-CD45-APC, anti-CD4-FITC, anti-CD8-PE, and anti-CD69-PerCP (BD PharMingen; all used at a 1:150 dilution). Antibodies used to detect CD4 and CD8 produce a mean fluorescence intensity shift of one decade (10-fold) over background of negative cells. Isotype controls were used in initial experiments to verify authentic CD4 and CD8 staining. Stained cells were subjected to 4-color flow cytometric analysis using a FACS Aria (Becton Dickinson) and CellQuest analysis software.

## Statistics

Significance of difference in viral titer between groups and between percentage of CD4<sup>+</sup> cells in infiltrates was determined by *t* test. The nonparametric Kruskal-Wallis test was used to determine significance of difference in disease scores between groups on individual days.

## Acknowledgements

We are indebted to Bob Silverman for sending us the RNase L<sup>-/-</sup> mice. The technical assistance of Mike Satzer, Hong Wang, and Sherri Koehm is greatly appreciated. We thank members of the Blight, Diamond, Leib, Morrison, Pekosz, Stuart, Wang and Yu laboratories, and Paul Olivo, for helpful advice and discussion. This work was supported by American Heart Association predoctoral fellowship 310042Z and Public Health Service awards CA75052 and AI57573.


## References

- Al-khatib K, Williams BR, Silverman RH, Halford W, Carr DJ. The murine double-stranded RNA-dependent protein kinase PKR and the murine 2',5'-oligoadenylate synthetase-dependent RNase L are required for IFN $\beta$ -mediated resistance against herpes simplex virus type 1 in primary trigeminal ganglion culture. *Virology* 2003;313:126–135. [PubMed: 12951027]
- Al-khatib K, Williams BR, Silverman RH, Halford W, Carr DJ. Dichotomy between survival and lytic gene expression in RNase L- and PKR-deficient mice transduced with an adenoviral vector expressing murine IFN-beta following ocular HSV-1 infection. *Exp Eye Res* 2005;80:167–173. [PubMed: 15670795]
- Al-khatib K, Williams BR, Silverman RH, Halford W, Carr DJ. Distinctive roles for 2',5'-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-beta. *J Immunol* 2004;172:5638–5647. [PubMed: 15100308]
- Austin BA, James C, Silverman RH, Carr DJ. Critical role for the oligoadenylate synthetase/RNase L pathway in response to IFN- $\beta$  during acute ocular herpes simplex virus type 1 infection. *J Immunol* 2005;175:1101–1106.
- Carr DJ, Al-Khatib K, James CM, Silverman R. Interferon- $\beta$  suppresses herpes simplex virus type 1 replication in trigeminal ganglion cells through an RNase L-dependent pathway. *J Neuroimmunol* 2003;141:40–46. [PubMed: 12965252]
- Cassady KA, Gross M, Roizman B. The herpes simplex virus US11 protein effectively compensates for the gamma 1 (34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. *J Virol* 1998a; 72:8620–8626. [PubMed: 9765401]
- Cassady KA, Gross M, Roizman B. The second-site mutation in the herpes simplex virus recombinants lacking the gamma 134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. *J Virol* 1998b;72:7005–7011. [PubMed: 9696792]
- Castelli JC, Hassel BA, Maran A, Paranjape J, Hewitt JA, Li XL, Hsu YT, Silverman RH, Youle RJ. The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis. *Cell Death Differ* 1998;5:313–320. [PubMed: 10200477]
- Cayley PI, Davies JA, McCullagh KG, Kerr IM. Activation of the ppp (A2'p)nA system in interferon-treated, herpes simplex virus-infected cells and evidence for novel inhibitors of the ppp(A2'p)nA-dependent RNase. *Eur J Biochem* 1984;143:165–174. [PubMed: 6088228]
- Floyd-Smith G. (2'-5')An-dependent endoribonuclease: enzyme levels are regulated by IFN beta, IFN gamma, and cell culture conditions. *J Cell Biochem* 1988;38:13–21. [PubMed: 3146577]
- Gerety SJ, Rundell MK, Dal Canto MC, Miller SD. Class II-restricted T cell responses in Theiler's murine encephalomyelitis virus-induced demyelinating disease. VI Potentiation of demyelination with and characterization of an immunopathologic CD4<sup>+</sup> T cell line specific for an immunodominant VP2 epitope. *J Immunol* 1994;152:919–929. [PubMed: 7506740]
- Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. *J Exp Med* 2005;202:1087–1098. [PubMed: 16230476]


- Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. *J Gen Virol* 2001;82:845–53. [PubMed: 11257190]
- Harle P, Cull V, Guo L, Papin J, Lawson C, Carr DJ. Transient transfection of mouse fibroblasts with type I interferon transgenes provides various degrees of protection against herpes simplex virus infection. *Antiviral Res* 2002a;56:39–49. [PubMed: 12323398]
- Harle P, Cull VF, Agbaga MP, Silverman RF, Williams BR, James C, Carr DJ. Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication. *J Virol* 2002b;76:6558–6567. [PubMed: 12050368]
- Harle P, Noisakran S, Carr DJ. The application of a plasmid DNA encoding IFN-alpha 1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice. *J Immunol* 2001;166:1803–1812. [PubMed: 11160227]
- He B, Gross M, Roizman B. The gamma (1) 34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. *Proc Natl Acad Sci USA* 1997;94:843–848. [PubMed: 9023344]
- Hendricks RL, Weber PC, Taylor JL, Koumbis A, Tumpsey TM, Glorioso JC. Endogenously produced interferon alpha protects mice from herpes simplex virus type 1 corneal disease. *J Gen Virol* 1991;72:1601–1610. [PubMed: 1649898]
- Keadle TL, Morris JL, Pepose JS, Stuart PM. CD4(+) and CD8(+) cells are key participants in the development of recurrent herpetic stromal keratitis in mice. *Microb Pathog* 2002;32:255–62. [PubMed: 12137752]
- Khabar KSA, Dhalla M, Siddiqui Y, Zhou A, Ahdal MN, Der SD, Silverman RH, Williams BRG. Effect of deficiency of the double-stranded RNA-dependent protein kinase, PKR, on antiviral resistance in the presence or absence of ribonuclease L: HSV-1 replication is particularly sensitive to deficiency of the major IFN-mediated enzymes. *J Interferon Cytokine Res* 2000;20:653–659. [PubMed: 10926208]
- Klotzbucher A, Mittnacht S, Kirchner H, Jacobsen H. Different effects of IFN gamma and IFN alpha/beta on "immediate early" gene expression of HSV-1. *Virology* 1990;179:487–491. [PubMed: 2171221]
- Knipe DM, Spang AE. Definition of a series of stages in the association of two herpesviral proteins with the cell nucleus. *J Virol* 1982;43:314–324. [PubMed: 6287005]
- Lane TE, Liu MT, Chen BP, Asensio VC, Samawi RM, Paoletti AD, Campbell IL, Kunkel SL, Fox HS, Buchmeier MJ. A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination. *J Virol* 2000;74:1415–1424. [PubMed: 10627552]
- Lausch RN, Su YH, Ritchie M, Oakes JE. Evidence endogenous interferon production contributed to the lack of ocular virulence of an HSV intertypic recombinant. *Curr Eye Res* 1991;10:39–45. [PubMed: 1650672]
- Leib DA, Harrison TE, Laslo KM, Machalek MA, Moorman NJ, Virgin HW. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. *J Exp Med* 1999;189:663–672. [PubMed: 9989981]
- Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. *Proc Natl Acad Sci USA* 2000;97:6097–6101. [PubMed: 10801979]
- Leitner WW, Hwang LN, Devere MJ, Zhou A, Silverman RH, Williams BRG, Dubensky TW, Ying H, Restifo NP. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. *Nat Med* 2003;9:33–39. [PubMed: 12496961]
- Marten NW, Stohlman SA, Bergmann CC. MHV infection of the CNS: mechanisms of immune-mediated control. *Viral Immunol* 2001;14:1–18. [PubMed: 11270593]
- Milligan GN, Bernstein DI. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. *Virology* 1995;212:481–489. [PubMed: 7571418]




- Milligan GN, Dudley-McClain KL, Young CG, Chu CF. T-cell-mediated mechanisms involved in resolution of genital herpes simplex virus type 2 (HSV-2) infection of mice. *J Reprod Immunol* 2004;61:115–127. [PubMed: 15063634]
- Mitnacht S, Straub P, Kirchner H, Jacobsen H. Interferon treatment inhibits onset of herpes simplex virus immediate-early transcription. *Virology* 1988;164:201–210. [PubMed: 2834869]
- Morrison LA, Da Costa XJ, Knipe DM. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. *Virology* 1998;243:178–187. [PubMed: 9527927]
- Morrison LA, Knipe DM. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. *Virology* 1996;320:402–413. [PubMed: 8661391]
- Murphy JA, Duerst RJ, Smith TJ, Morrison LA. Herpes simplex virus type 2 virion host shutoff protein regulates alpha/beta interferon but not adaptive immune responses during primary infection in vivo. *J Virol* 2003;77:9337–9345. [PubMed: 12915549]
- Niemaltowski MG, Rouse BT. Predominance of Th1 cells in ocular tissues during herpetic stromal keratitis. *J Immunol* 1992;149:3035–3039. [PubMed: 1357034]
- Noisakran S, Campbell IL, Carr DJ. Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. *J Immunol* 1999;162:4184–4190. [PubMed: 10201945]
- Noisakran S, Campbell IL, Carr DJ. IFN-alpha1 plasmid construct affords protection against HSV-1 infection in transfected L929 fibroblasts. *J Interferon Cytokine Res* 2000;20:107–115. [PubMed: 10670657]
- Oberman F, Panet A. Inhibition of transcription of herpes simplex virus immediate early genes in interferon-treated human cells. *J Gen Virol* 1988;69:1167–1177. [PubMed: 2455018]
- Oberman F, Panet A. Characterization of the early steps of herpes simplex virus replication in interferon-treated human cells. *J Interferon Res* 1989;9:563–571. [PubMed: 2477472]
- Osorio Y, Cai S, Hofman FM, Brown DJ, Ghiasi H. Involvement of CD8+ T-cells in exacerbation of corneal scarring in mice. *Curr Eye Res* 2004;29:145–51. [PubMed: 15512961]
- Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM, Lieberman J. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infections. *Nature* 2006;439:89–94. [PubMed: 16306938]
- Rowell JF, Griffin DE. The inflammatory response to nonfatal Sindbis virus infection of the nervous system is more severe in SJL than in BALB/c mice and is associated with low levels of IL-4 mRNA and high levels of IL-10-producing CD4+ T cells. *J Immunol* 1999;162:1624–1632. [PubMed: 9973422]
- Silverman RH, Zhou A, Auerbach MB, Kish D, Gorbachev A, Fairchild RL. Skin allograft rejection is suppressed in mice lacking the antiviral enzyme, 2',5'-oligoadenylate-dependent RNase L. *Viral Immunol* 2002;15:77–88. [PubMed: 11952148]
- Smith TJ, Silverman RH, Leib DA. RNase L activity does not contribute to host RNA degradation induced by herpes simplex virus infection. *J Gen Virol* 2003;84:925–928. [PubMed: 12655093]
- Zheng X, Silverman RH, Zhou A, Goto T, Kwon BS, Kaufman HE, Hill JM. Increased severity of HSV-1 keratitis and mortality in mice lacking the 2-5A-dependent RNase L gene. *Invest Ophthalmol Vis Sci* 2002;42:120–126. [PubMed: 11133856]
- Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C, Silverman RH. Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. *EMBO J* 1997;16:6355–6363. [PubMed: 9351818]
- Zhou A, Paranjape JM, Brown TL, Hassel BA, Nie H, Shah S, Galinski B, Silverman RH. Impact of RNase L overexpression on viral and cellular growth and death. *J Interferon Cytokine Res* 1998;18:953–961. [PubMed: 9858317]




**Figure 1. Replication of HSV-2 in the genital mucosa of wild-type B6 and RNase L<sup>-/-</sup> mice**  
Mice were infected i.vag. with  $2 \times 10^6$  pfu/mouse of HSV-2 strain 333. A) Titer of virus in vaginal swab samples taken 9 hr to 4 days post-infection was determined by standard plaque assay on Vero cells. Data points represent the geometric mean  $\pm$  standard error of the mean for 6 mice per group in one of two experiments with similar results.




**Figure 2. Severity of genital disease in wild-type B6 and RNase L<sup>-/-</sup> mice infected with HSV-2** Mice were infected with  $2 \times 10^6$  pfu/mouse i.vag. with HSV-2 strain 333. A) Genital disease scores for 33 wild-type B6 and 43 RNase L<sup>-/-</sup> mice, and B) change in weight for 22 wild-type B6 and 28 RNase L<sup>-/-</sup> mice were recorded daily. Values represent the arithmetic mean  $\pm$  standard error of the mean. \*p value <0.001; \*\*p value  $\leq$ 0.0001.



**Figure 3. Survival time of mice after infection with a lethal dose of HSV-2**  
 Wild-type B6 and RNase L<sup>-/-</sup> mice were infected i.vag. with  $2 \times 10^6$  pfu/mouse with HSV-2 strain 333 and survival was recorded daily. n=19 for wild-type and n=22 for RNase L<sup>-/-</sup> mice. \*\*p value=0.0003 on day 6; \*p value= 0.0252 on day 7 post-infection.



**Figure 4. Replication of HSV-2 in the nervous tissues of wild-type B6 and RNase L<sup>-/-</sup> mice**  
 A) Groups of mice surviving to day 6 post-infection with HSV-2 were sacrificed, and brain, brainstem, and spinal cord tissues were dissected. Viral titers in disrupted tissues were determined by plaque assay. The dashed line indicates the limit of detection. n=13 for wild-type B6 mice and n=22 for RNase L<sup>-/-</sup> mice. \*p value=0.0152; \*\*p value=0.0116. B) Groups of mice were injected intracranially with  $5 \times 10^3$  PFU of HSV-2 and sacrificed 1, 2 or 3 days post-infection. Brain tissue was removed and viral titers in disrupted tissues were determined by plaque assay. Values represent the geometric mean  $\pm$  SEM of 4 to 8 mice per group.



**Figure 5. T lymphocyte infiltration into the genital tract and spinal cord**

Groups of RNase L<sup>-/-</sup> or wild-type mice were uninfected or infected with HSV-2. After 6 days, genital tracts and lumbosacral spinal cords were dissected. Mononuclear cells enzymatically released from tissues of individual mice were stained with anti-CD45-APC, anti-CD8-PE, anti-CD4-FITC, and anti-CD69-PerCP and analyzed by flow cytometry. Regions were defined by CD45<sup>+</sup> cells of size and granularity typically associated with lymphocytes. Data from two individual experiments were pooled and represent A and B) the mean percentage ± SD of CD8<sup>+</sup> and CD4<sup>+</sup> T cells, respectively, recovered from 6 individual mice, and C and D) the mean number of CD8<sup>+</sup> and CD4<sup>+</sup> T cells, respectively, recovered. \*\*p value=0.0301–0.0379; \*p value=0.0438.